Published in Ann Rheum Dis on May 16, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
Physicochemical characterization of Remsima. MAbs (2014) 1.42
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
Antibodies to watch in 2015. MAbs (2015) 1.28
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis (2016) 1.11
Biosimilars in rheumatology: what the clinician should know. RMD Open (2015) 1.09
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis (2016) 1.08
Clinical trials for authorized biosimilars in the European Union: a systematic review. Br J Clin Pharmacol (2016) 1.08
Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol (2015) 1.07
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther (2015) 1.07
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther (2014) 1.06
Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives. Can J Gastroenterol Hepatol (2014) 1.05
Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J (2013) 1.02
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis (2015) 1.01
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther (2016) 0.95
The changing landscape of biosimilars in rheumatology. Ann Rheum Dis (2016) 0.95
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol (2015) 0.94
Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis (2013) 0.94
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther (2016) 0.93
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ (2014) 0.92
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci (2014) 0.91
Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol (2016) 0.91
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therap Adv Gastroenterol (2016) 0.90
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int (2016) 0.89
Clinical considerations for biosimilar antibodies. EJC Suppl (2013) 0.89
Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France. MAbs (2014) 0.86
Biologicals in rheumatoid arthritis: current and future. RMD Open (2015) 0.84
Biosimilars: what do patients need to consider? RMD Open (2015) 0.83
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence. BioDrugs (2016) 0.82
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol (2016) 0.82
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol (2015) 0.81
Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res (2016) 0.81
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol (2015) 0.80
IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol (2015) 0.80
Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr (2015) 0.80
A practical guide about biosimilar data for health care providers treating inflammatory diseases. Biologics (2017) 0.79
Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open (2015) 0.79
Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clin Rheumatol (2015) 0.78
Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis (2015) 0.78
[Biosimilars : Current state of the build up to series production]. Z Rheumatol (2013) 0.78
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol (2016) 0.77
Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol (2014) 0.77
Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis. Clin Rheumatol (2015) 0.77
A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects. BioDrugs (2015) 0.76
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence. BioDrugs (2016) 0.76
[Biosimilars in rheumatology : Development and results of clinical trials]. Z Rheumatol (2015) 0.76
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open (2017) 0.75
Biomedical and Market Issues Surrounding the Advent of Biosimilars. Dermatol Ther (Heidelb) (2016) 0.75
Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics (2017) 0.75
Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World J Gastroenterol (2017) 0.75
Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS One (2017) 0.75
Evaluating imbalances of adverse events during biosimilar development. MAbs (2016) 0.75
Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol (2016) 0.75
Epidemiology research in rheumatology-progress and pitfalls. Nat Rev Rheumatol (2015) 0.75
Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: results of a French web-based survey. MAbs (2016) 0.75
Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol (2017) 0.75
Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars. Hosp Pharm (2015) 0.75
The Role of Biosimilars in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2016) 0.75
Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatol Int (2017) 0.75
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci (2017) 0.75
Unanswered questions in the management of axial spondyloarthritis: an opinion piece. Clin Rheumatol (2014) 0.75
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study. Drugs R D (2017) 0.75
[Psoriatic arthritis : Current therapeutic standards]. Z Rheumatol (2017) 0.75
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol (2017) 0.75
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol (2017) 0.75
Update on biosimilars in rheumatology. Inflammopharmacology (2017) 0.75
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? RMD Open (2017) 0.75
[Regulatory aspects of biosimilars : Myths and facts]. Z Rheumatol (2015) 0.75
Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. Clin Rheumatol (2017) 0.75
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front Pharmacol (2017) 0.75
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therap Adv Gastroenterol (2017) 0.75
Clinical Trial Design in Juvenile Idiopathic Arthritis. Paediatr Drugs (2017) 0.75
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum (2006) 2.11
Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med (2006) 2.05
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.67
Evaluating equivalence and noninferiority trials. Am J Health Syst Pharm (2010) 1.48
A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol (2006) 1.46
Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis (2003) 1.01
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med (2009) 2.55
Adipocytokines in synovial fluid. JAMA (2003) 2.48
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg (2003) 1.95
Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res (2004) 1.88
Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer (2005) 1.86
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol (2006) 1.74
The potential of adiponectin in driving arthritis. J Immunol (2006) 1.70
Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med (2010) 1.67
In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum (2004) 1.55
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res (2002) 1.52
Which patients benefit from preoperative chemoradiotherapy for intermediate staged rectal cancer? Onkologie (2011) 1.42
Aberration compensation for objective phase curvature in phase holographic microscopy. Opt Lett (2012) 1.40
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis (2013) 1.39
Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery. Int J Urol (2014) 1.38
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
HIV prevalence and related risk behaviours among female sex workers in Iran: results of the national biobehavioural survey, 2010. Sex Transm Infect (2013) 1.29
Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum (2002) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up. Int J Radiat Oncol Biol Phys (2013) 1.22
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis (2012) 1.21
Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Ann Rheum Dis (2012) 1.20
Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol (2010) 1.19
Molecular profile of synovial fibroblasts in rheumatoid arthritis depends on the stage of proliferation. Arthritis Res (2002) 1.19
Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol (2010) 1.18
Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum (2010) 1.17
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther (2006) 1.17
Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys (2007) 1.17
A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol (2008) 1.17
Effects of supervised exercise therapy in patients receiving radiotherapy for breast cancer. Yonsei Med J (2008) 1.16
Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol (2003) 1.15
Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis (2006) 1.15
Gout--current diagnosis and treatment. Dtsch Arztebl Int (2009) 1.14
The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol (2008) 1.13
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol (2012) 1.13
Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol (2005) 1.12
Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis (2012) 1.11
Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A (2010) 1.11
Therapeutic management of pyoderma gangrenosum. Arthritis Rheum (2004) 1.10
Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat (2011) 1.09
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum (2004) 1.07
Synchrotron X-ray imaging for nondestructive monitoring of sap flow dynamics through xylem vessel elements in rice leaves. New Phytol (2010) 1.07
A systematic review on the Rosa canina effect and efficacy profiles. Phytother Res (2008) 1.07
Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol (2011) 1.06
Native albumin for targeted drug delivery. Expert Opin Drug Deliv (2010) 1.06
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat (2010) 1.05
X-ray imaging of various biological samples using a phase-contrast hard X-ray microscope. Microsc Res Tech (2008) 1.04
Pelvic insufficiency fracture after pelvic irradiation in uterine cervix cancer. Gynecol Oncol (2002) 1.03
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat (2012) 1.02
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) (2011) 1.02
The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int (2009) 1.02
Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother Pharmacol (2008) 1.02
Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem (2005) 1.01
Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2004) 1.01
Micro-PIV measurements of blood flow in extraembryonic blood vessels of chicken embryos. Physiol Meas (2007) 1.01
Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res (2011) 1.01
Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum (2012) 1.01
Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci (2011) 1.00
Current immunotherapy in rheumatoid arthritis. Immunotherapy (2013) 1.00
[Serial whole-body cryotherapy in the criostream for inflammatory rheumatic diseases. A pilot study]. Med Klin (Munich) (2008) 1.00
Radiation therapy for gastric cancer bleeding. Tumori (2010) 0.99
Bile acids mimic oxidative stress induced upregulation of thioredoxin reductase in colon cancer cell lines. Carcinogenesis (2002) 0.99
Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma. Radiother Oncol (2009) 0.99
Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol (2007) 0.99
The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol (2011) 0.98
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis (2012) 0.98
Experimental analysis of the blood-sucking mechanism of female mosquitoes. J Exp Biol (2011) 0.98
The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol (2005) 0.98
Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int (2011) 0.97
The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol (2007) 0.97
The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum (2005) 0.96
Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther (2010) 0.95
Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol (2006) 0.95
[Bronchobiliary fistula associated with combined abscess of lung and liver]. Med Klin (Munich) (2004) 0.95
Low grade MALT lymphoma of the stomach: treatment outcome with radiotherapy alone. Yonsei Med J (2002) 0.95
Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol (2011) 0.94
The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol (2007) 0.94
Gold nanoparticle flow sensors designed for dynamic X-ray imaging in biofluids. ACS Nano (2010) 0.94
Anti-inflammatory effects of aromatic-turmerone through blocking of NF-κB, JNK, and p38 MAPK signaling pathways in amyloid β-stimulated microglia. Int Immunopharmacol (2012) 0.93
Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. Arthritis Rheum (2007) 0.93
Bile acid induces cyclo-oxygenase-2 expression in cultured human pharyngeal cells: a possible mechanism of carcinogenesis in the upper aerodigestive tract by laryngopharyngeal reflux. Laryngoscope (2003) 0.93
Improving the compressive strength of bioceramic robocast scaffolds by polymer infiltration. Acta Biomater (2010) 0.93